HRP20150807T1 - PRIPRAVCI KOJI SADRŽE PROTUTIJELO, ILI NJEGOV FRAGMENT, SPECIFIÄŚNO ZA aP2, NAMIJENJENO UPOTREBI U LIJEÄŚENJU DIJABETESA, NEPODNOŠENJA GLUKOZE ILI OTPORNOSTI NA INZULIN UZROKOVANE PRETILOŠÄ†U - Google Patents
PRIPRAVCI KOJI SADRŽE PROTUTIJELO, ILI NJEGOV FRAGMENT, SPECIFIÄŚNO ZA aP2, NAMIJENJENO UPOTREBI U LIJEÄŚENJU DIJABETESA, NEPODNOŠENJA GLUKOZE ILI OTPORNOSTI NA INZULIN UZROKOVANE PRETILOŠÄ†U Download PDFInfo
- Publication number
- HRP20150807T1 HRP20150807T1 HRP20150807TT HRP20150807T HRP20150807T1 HR P20150807 T1 HRP20150807 T1 HR P20150807T1 HR P20150807T T HRP20150807T T HR P20150807TT HR P20150807 T HRP20150807 T HR P20150807T HR P20150807 T1 HRP20150807 T1 HR P20150807T1
- Authority
- HR
- Croatia
- Prior art keywords
- residues
- residue
- preparation
- obesity
- fragment
- Prior art date
Links
- 208000002705 Glucose Intolerance Diseases 0.000 title claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 title claims 2
- 206010022489 Insulin Resistance Diseases 0.000 title claims 2
- 208000008589 Obesity Diseases 0.000 title claims 2
- 206010012601 diabetes mellitus Diseases 0.000 title claims 2
- 239000012634 fragment Substances 0.000 title claims 2
- 235000020824 obesity Nutrition 0.000 title claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 7
- 210000002966 serum Anatomy 0.000 claims 3
- 206010033307 Overweight Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Zoology (AREA)
Claims (6)
1. Pripravak koji sadrži protutijelo specifično za aP2, ili njegov fragment koji se veže na aP2, namijenjen upotrebi u postupku liječenja dijabetesa ili smanjenja nepodnošenja glukoze ili smanjenja otpornosti na inzulin uzrokovane pretilošću, naznačen time što se postupak sastoji u primjeni pripravka na subjekt i što primjena pripravka na subjektu smanjuje koncentraciju aP2 u serumu.
2. Pripravak namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 1, naznačen time što subjekt ima prekomjernu težinu, pretio je i/ili ima razinu aP2 u serumu višu od 20 µg/l.
3. Pripravak namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 1, naznačen time što je koncentracija aP2 u serumu snižena za najmanje 10%.
4. Pripravak namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 1, naznačen time što se protutijelo specifično za aP2 veže na diskontinuirani epitop aP2.
5. Pripravak namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 4, naznačen time što je epitop u otopini izložen na površini trodimenzijske strukture aP2.
6. Pripravak namijenjen upotrebi u postupku u skladu s patentnim zahtjevom 4, naznačen time što epitop sadrži najmanje jedan od sljedećih sljedova: ostatke 1-5, ostatak 22, ostatke 36-37, ostatke 46-47, ostatak 57, ostatke 59-60, ostatak 78, ostatak 80, ostatak 89, ostatke 97-101, ostatke 110-112, ostatak 122 iz SEQ ID NO: 4.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20925109P | 2009-03-05 | 2009-03-05 | |
| US29917010P | 2010-01-28 | 2010-01-28 | |
| EP10707783.6A EP2403605B1 (en) | 2009-03-05 | 2010-03-05 | Compositions comprising an aP2-specific antibody or a fragment thereof for use in treating diabetes, glucose intolerance or obesity-induced insulin resistance |
| PCT/US2010/026305 WO2010102171A2 (en) | 2009-03-05 | 2010-03-05 | Secreted ap2 and methods of inhibiting same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150807T1 true HRP20150807T1 (hr) | 2015-09-11 |
Family
ID=42312973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150807TT HRP20150807T1 (hr) | 2009-03-05 | 2015-07-23 | PRIPRAVCI KOJI SADRŽE PROTUTIJELO, ILI NJEGOV FRAGMENT, SPECIFIÄŚNO ZA aP2, NAMIJENJENO UPOTREBI U LIJEÄŚENJU DIJABETESA, NEPODNOŠENJA GLUKOZE ILI OTPORNOSTI NA INZULIN UZROKOVANE PRETILOŠÄ†U |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20120134998A1 (hr) |
| EP (2) | EP2403605B1 (hr) |
| JP (4) | JP5984396B2 (hr) |
| CN (3) | CN107149679B (hr) |
| AU (2) | AU2010221182B2 (hr) |
| BR (1) | BRPI1013358A2 (hr) |
| CA (1) | CA2753991C (hr) |
| DK (1) | DK2403605T3 (hr) |
| ES (1) | ES2542737T3 (hr) |
| HK (1) | HK1212923A1 (hr) |
| HR (1) | HRP20150807T1 (hr) |
| PL (1) | PL2403605T3 (hr) |
| PT (1) | PT2403605E (hr) |
| SI (1) | SI2403605T1 (hr) |
| SM (1) | SMT201500190B (hr) |
| WO (1) | WO2010102171A2 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2403605T3 (pl) | 2009-03-05 | 2016-01-29 | Harvard College | Kompozycje zawierające przeciwciało specyficzne względem aP2 albo jego fragment do zastosowania w leczeniu cukrzycy, nietolerancji glukozy lub insulinooporności wywołanej otyłością |
| CN103665139A (zh) * | 2013-11-29 | 2014-03-26 | 中国药科大学 | 一种脂肪细胞型脂肪酸结合蛋白及其单克隆抗体的制备和应用 |
| JP6223376B2 (ja) | 2014-03-24 | 2017-11-01 | 花王株式会社 | Ｇｉｐ上昇抑制剤の評価又は選択方法 |
| TW201702271A (zh) | 2015-04-30 | 2017-01-16 | 哈佛大學校長及研究員協會 | 治療代謝病症之抗－ａｐ２抗體及抗原結合劑 |
| AU2016276942B2 (en) | 2015-06-10 | 2022-08-25 | Children's National Medical Center | Adipocyte-derived exosomes, and compositions, kits, and methods of using the same for detection and screening |
| JP6558729B2 (ja) * | 2015-06-15 | 2019-08-14 | 北海道公立大学法人 札幌医科大学 | 糸球体障害の検査方法 |
| EP3475299A4 (en) * | 2016-06-27 | 2020-03-18 | President and Fellows of Harvard College | COMPOUNDS USEFUL FOR TREATING METABOLIC DISORDERS |
| US10792119B2 (en) | 2017-05-22 | 2020-10-06 | Ethicon Llc | Robotic arm cart and uses therefor |
| US10856948B2 (en) | 2017-05-31 | 2020-12-08 | Verb Surgical Inc. | Cart for robotic arms and method and apparatus for registering cart to surgical table |
| CA3066733A1 (en) | 2017-06-09 | 2018-12-13 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
| US10913145B2 (en) | 2017-06-20 | 2021-02-09 | Verb Surgical Inc. | Cart for robotic arms and method and apparatus for cartridge or magazine loading of arms |
| CN109971761B (zh) * | 2019-04-12 | 2022-07-29 | 宁夏大学 | 脂肪酸结合蛋白4的小干扰rna及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4360C (da) | 1901-11-18 | Bethlehem Steel Corp | Anordning til Regulering af Temperaturen i et Metalbad til Brug ved Hærdning. | |
| DK1507C (da) | 1898-03-21 | Peter Holger Hansen | Fremgangsmaade til Fremstilling af en hornagtig Masse af Kasein. | |
| DE69130741T2 (de) * | 1990-05-16 | 1999-07-29 | Dana Farber Cancer Inst Inc | Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung |
| US5889167A (en) | 1996-05-22 | 1999-03-30 | Merck & Co., Inc. | Synthetic glucagon binding proteins |
| CA2344300A1 (en) * | 1998-09-17 | 2000-03-23 | Jeffrey A. Robl | Method for treating atherosclerosis employing an ap2 inhibitor and combination |
| DE60041246D1 (de) * | 1999-02-12 | 2009-02-12 | Harvard College | Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren |
| US6548529B1 (en) * | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| US7390824B1 (en) * | 1999-09-07 | 2008-06-24 | Bristol-Myers Squibb Company | Method for treating diabetes employing an aP2 inhibitor and combination |
| WO2002098917A2 (en) * | 2001-02-12 | 2002-12-12 | Curagen Corporation | Human proteins and nucleic acids encoding same |
| US6919323B2 (en) * | 2001-07-13 | 2005-07-19 | Bristol-Myers Squibb Company | Pyridazinone inhibitors of fatty acid binding protein and method |
| AU2002348276A1 (en) * | 2001-11-16 | 2003-06-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| TW200518768A (en) * | 2003-11-17 | 2005-06-16 | Pepgen Corp | Methods for treatment of obesity and for promotion of weight loss |
| DE102006034607A1 (de) * | 2005-07-21 | 2007-01-25 | Biovendor Laboratory Medicine, Inc. | Verfahren zur Bestimmung der Konzentration der adipozytären Form des fatty acid binding protein (A-FABP, FABP4, P2) |
| ATE468128T1 (de) * | 2005-07-21 | 2010-06-15 | Biovendor Lab Medicine Inc | Verfahren zur bestimmung der konzentration der adipozytaren form des fatty acid bindung protein (a-fabp, fabp4, ap2) |
| ES2651503T3 (es) | 2008-11-20 | 2018-01-26 | Mesoblast, Inc. | Método para tratar o prevenir una disfunción pancreática |
| PL2403605T3 (pl) | 2009-03-05 | 2016-01-29 | Harvard College | Kompozycje zawierające przeciwciało specyficzne względem aP2 albo jego fragment do zastosowania w leczeniu cukrzycy, nietolerancji glukozy lub insulinooporności wywołanej otyłością |
-
2010
- 2010-03-05 PL PL10707783T patent/PL2403605T3/pl unknown
- 2010-03-05 ES ES10707783.6T patent/ES2542737T3/es active Active
- 2010-03-05 EP EP10707783.6A patent/EP2403605B1/en active Active
- 2010-03-05 CN CN201710076996.8A patent/CN107149679B/zh active Active
- 2010-03-05 CN CN2010800198008A patent/CN102639149A/zh active Pending
- 2010-03-05 JP JP2011553125A patent/JP5984396B2/ja active Active
- 2010-03-05 BR BRPI1013358A patent/BRPI1013358A2/pt not_active Application Discontinuation
- 2010-03-05 US US13/203,880 patent/US20120134998A1/en not_active Abandoned
- 2010-03-05 PT PT107077836T patent/PT2403605E/pt unknown
- 2010-03-05 AU AU2010221182A patent/AU2010221182B2/en active Active
- 2010-03-05 CN CN201710076983.0A patent/CN107141353A/zh active Pending
- 2010-03-05 SI SI201030995T patent/SI2403605T1/sl unknown
- 2010-03-05 CA CA2753991A patent/CA2753991C/en active Active
- 2010-03-05 WO PCT/US2010/026305 patent/WO2010102171A2/en active Application Filing
- 2010-03-05 DK DK10707783.6T patent/DK2403605T3/en active
- 2010-03-05 EP EP15154201.6A patent/EP2898898A1/en active Pending
-
2015
- 2015-03-20 JP JP2015057399A patent/JP5966039B2/ja active Active
- 2015-07-23 HR HRP20150807TT patent/HRP20150807T1/hr unknown
- 2015-08-06 SM SM201500190T patent/SMT201500190B/xx unknown
-
2016
- 2016-01-29 HK HK16101022.2A patent/HK1212923A1/zh unknown
- 2016-04-07 JP JP2016076997A patent/JP6301995B2/ja active Active
- 2016-04-07 US US15/093,508 patent/US9879078B2/en active Active
- 2016-07-04 JP JP2016132195A patent/JP2016180000A/ja active Pending
- 2016-10-27 AU AU2016250423A patent/AU2016250423A1/en not_active Abandoned
-
2017
- 2017-12-21 US US15/851,040 patent/US10882901B2/en active Active
-
2020
- 2020-11-23 US US17/102,329 patent/US11685774B2/en active Active
-
2023
- 2023-06-26 US US18/341,404 patent/US20240209072A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150807T1 (hr) | PRIPRAVCI KOJI SADRŽE PROTUTIJELO, ILI NJEGOV FRAGMENT, SPECIFIÄŚNO ZA aP2, NAMIJENJENO UPOTREBI U LIJEÄŚENJU DIJABETESA, NEPODNOŠENJA GLUKOZE ILI OTPORNOSTI NA INZULIN UZROKOVANE PRETILOŠÄ†U | |
| HRP20191843T1 (hr) | Mikobakterijski antigenski pripravak | |
| MX2011000768A (es) | Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. | |
| BR112017026330A2 (pt) | molécula de ligação de lag-3 capaz de ligação tanto o lag-3 humano quanto ao lag-3 de macaco cynomolgus | |
| MX353319B (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
| AR088289A1 (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion | |
| MY162988A (en) | Method for treating joint damage | |
| MA46219B1 (fr) | Composés de co-agonistes du glucagon et du glp-1 | |
| NZ734892A (en) | Amatoxin-antibody conjugates | |
| MX352338B (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
| BRPI0721003B8 (pt) | composições e uso | |
| NZ601793A (en) | Methods and compositions for diagnosis and treatment of cancer | |
| BRPI1014522B8 (pt) | anticorpo anti-actriib ou fragmento funcional, processo de produção dos mesmos, composição farmacêutica e usos | |
| MY166282A (en) | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses | |
| WO2010090471A3 (ko) | 제1형 당뇨병의 신규한 진단 마커 | |
| WO2008121615A3 (en) | Antibody formulation | |
| BR112013011065A2 (pt) | "anticorpo anti-il-23p19 ou seu fragmento de ligação ao antígeno, composição farmacêutica, uso de um anticorpo ou do fragmento de ligação, método para inibir a ligação da il-23 para o receptor da il-23 em uma célula de mamífero, polinucleotídeo isolado e kit" | |
| MY173097A (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
| EA201170053A1 (ru) | Способ получения и сушки твердого разагилина в форме основания | |
| NZ599827A (en) | Use of il-23 antagonists for treatment of infection | |
| WO2013009869A3 (en) | Akt-specific capture agents, compositions, and methods of using and making | |
| BRPI0611820B8 (pt) | método de identificar uma infecção por e. canis ou e. chaffeensis | |
| DOP2010000121A (es) | Procedimiento para la preparacion de una bebida fermentada | |
| JP2010532766A5 (hr) | ||
| JP2016523910A5 (hr) |